Pre-Clinical Research
Filter News
Found 6,711 articles
-
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
-
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
7/19/2019
Aridis Pharmaceuticals, Inc. announced that the European Medicines Agency has granted Orphan Drug Designation to AR-501, the Company's inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.
-
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
7/19/2019
Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets.
-
BioSpace Global Roundup, July 18
7/18/2019
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy. -
Discovery shows how difficult-to-treat prostate cancer evades immune system
7/18/2019
Study reports pre-clinical development of novel treatment and potential for combination use with immunotherapy drugs
-
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
7/18/2019
Collaboration advances Silence's proprietary platform in the growing field of RNAi technology
-
Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
7/17/2019
Summit Therapeutics plc announced that it highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat all gonorrhoea, including multi-drug and extensively-drug resistant strains, in a poster presentation at the STI & HIV World Congress in Vancouver, Canada.
-
EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38α Kinase Inhibitor Neflamapimod on the Neurodegenerative Process
7/17/2019
Presentations at Late Breaker Session at Alzheimer's Association International Conference (AAIC) 2019
-
PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema
7/17/2019
Wholly owned program adds to Company’s growing internal pipeline focused on lymphatic targeting and tissue-selective immunomodulation
-
Scientists Identify Differences Between Relapsing/Remitting and Progressive Multiple Sclerosis
7/16/2019
Multiple sclerosis (MS) is an often-disabling disease of the central nervous system caused by damage to the myelin coating around the nerves. -
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
-
AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease
7/15/2019
AVROBIO, Inc. announced the first kidney biopsy result and additional positive data from two ongoing clinical trials of its AVR‑RD‑01 investigational gene therapy in Fabry disease.
-
Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split
7/15/2019
Approximately 80% of cancers are from solid tumors and metastasis is the main cause of patient death.
-
Endotronix Enrolls First Patient in SIRONA II CE Mark Trial
7/15/2019
Study to support European clearance of Cordella™ Pulmonary Artery Sensor System for treatment of patients with chronic heart failure
-
Ascentage Pharma announces first patient dosed in Phase I clinical trial of APG-2575 in China as the first China-made Bcl-2 Inhibitor
7/15/2019
Ascentage Pharma announced that the company recently dosed the first patient successfully in a Phase I clinical trial of APG-2575, a novel Bcl-2 selective inhibitor, for the treatment of hematologic malignancies in China.
-
Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
7/10/2019
Pan-RAF Program adds an Early Stage, Innovative, Precision Oncology Asset to Jazz Pharmaceuticals' Growing R&D Portfolio
-
Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers
7/9/2019
Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for treatment of patients with KRAS-mutated metastatic Colorectal Cancer (mCRC)
-
Blue Water Vaccines, Developing Universal Flu Vaccine, Completes $7m Financing Following Successful Preclinical Study
7/9/2019
Blue Water Vaccines, a company developing a universal flu vaccine based on technology developed at the University of Oxford, has closed a $7 million seed capital round led by CincyTech.
-
New HER-Vaxx Cancer Vaccine trial data presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer
7/8/2019
Imugene Limited, a clinical stage immuno-oncology company, announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.
-
Horizon Discovery’s SMARTvector shRNA Technology Deployed in Celyad’s Successful IND Filing for Next-Generation CAR-T Cell Therapy, CYAD-02
7/8/2019
Horizon Discovery Group plc, announced that Celyad, a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™ shRNA technology.